Merus N.V. (MRUS)
NASDAQ: MRUS · IEX Real-Time Price · USD
55.29
+0.48 (0.88%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Merus Employees
Merus had 229 employees as of December 31, 2023. The number of employees increased by 8 or 3.62% compared to the previous year.
Employees
229
Change (1Y)
8
Growth (1Y)
3.62%
Revenue / Employee
$167,410
Profits / Employee
-$653,511
Market Cap
3.66B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 229 | 8 | 3.62% |
Dec 31, 2022 | 221 | 46 | 26.29% |
Dec 31, 2021 | 175 | 34 | 24.11% |
Dec 31, 2020 | 141 | 9 | 6.82% |
Dec 31, 2019 | 132 | 34 | 34.69% |
Dec 31, 2018 | 98 | 15 | 18.07% |
Dec 31, 2017 | 83 | 32 | 62.75% |
Dec 31, 2016 | 51 | 18 | 54.55% |
Sep 30, 2015 | 33 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Perrigo Company | 9,140 |
Sotera Health Company | 3,000 |
Neogen | 2,640 |
Guardant Health | 1,779 |
Waystar Holding | 1,400 |
Alvotech | 1,026 |
Prestige Consumer Healthcare | 560 |
MRUS News
- 6 weeks ago - Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 7 weeks ago - Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 7 weeks ago - Merus Announces Pricing of Upsized Public Offering of Common Shares - GlobeNewsWire
- 7 weeks ago - Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 7 weeks ago - Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC - GlobeNewsWire
- 2 months ago - Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 2 months ago - Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting - GlobeNewsWire